Navigating the Intellectual Property Minefield: A Strategic Guide to Mitigating Patent Litigation Risks in M&A Due Diligence
Why Pharma M&A Is Really a Patent Acquisition Business When AstraZeneca paid $39 billion for Alexion in 2021, it wasn’t […]
A Strategic Guide to Capitalizing on Patent Expiry, Generic Entry, and Product Reformulation
The patent cliff is measurable, foreseeable, and still consistently underestimated. Between 2025 and 2030, the U.S. pharmaceutical market will surrender
The $700B Generic Drug Margin Trap — And How PAT/QbD Gets You Out
A deep strategic analysis of Process Analytical Technology and Quality by Design as instruments of competitive differentiation, IP defense, cost
The $700B Generic Drug Margin Trap — And How PAT/QbD Gets You Out Read Post »
How Chemical Patent Non-Infringement Strategy Wins Drug Markets
The complete analytical guide for pharma IP teams, portfolio managers, and generic entrants: from claim construction and Markush deconstruction to
How Chemical Patent Non-Infringement Strategy Wins Drug Markets Read Post »
The Small Molecule’s Resurgence: A Deep-Dive Strategic Analysis of FDA Approval Trends, IP Valuation, and Portfolio Economics for Pharma and Biotech Investors
1. The Approval Data That Rewrites the Narrative The dominant story in pharma investment circles for the better part of
The Authorized Generic Gambit: How Brand Pharma Weaponizes Its Own Patent Expiry
By the time a blockbuster drug’s first Paragraph IV challenger is ready to launch, the brand manufacturer has often already
The Authorized Generic Gambit: How Brand Pharma Weaponizes Its Own Patent Expiry Read Post »
Argentina’s $14B Pharma Market: IP Traps, Deregulation Windfalls, and the Exact Strategy to Profit from Both
Argentina’s pharmaceutical market is a $7.3 billion commercial arena projected to reach $14.2 billion by 2030 — and it is
The $400B Generic Drug Playbook: How Lipitor, Plavix, and Gleevec Were Won
The three most consequential generic drug launches in pharmaceutical history share almost nothing in surface mechanics. One ended in a
The $400B Generic Drug Playbook: How Lipitor, Plavix, and Gleevec Were Won Read Post »
Generic Drugs for Low-Income Markets: The Formulation, IP, and Regulatory Playbook
The global generic drug industry saves the U.S. healthcare system roughly $2.9 trillion per decade. In high-income markets, this model
Generic Drugs for Low-Income Markets: The Formulation, IP, and Regulatory Playbook Read Post »
